A share price of ImmunityBio Inc [IBRX] is currently trading at $3.01, down -4.14%. An important factor to consider is whether the stock is rising or falling in short-term value. The IBRX shares have gain 5.61% over the last week, with a monthly amount drifted -8.51%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
ImmunityBio Inc [NASDAQ: IBRX] stock has seen the most recent analyst activity on March 06, 2025, when H.C. Wainwright initiated its Buy rating and assigned the stock a price target of $8. Previously, BTIG Research started tracking the stock with Buy rating on January 10, 2025, and set its price target to $6. On May 12, 2023, downgrade downgraded it’s rating to Neutral and revised its price target to $4 on the stock. Jefferies started tracking the stock assigning a Buy rating and suggested a price target of $8 on August 03, 2022.
ImmunityBio Inc experienced fluctuations in its stock price throughout the past year between $2.28 and $10.53. Currently, Wall Street analysts expect the stock to reach $6 within the next 12 months. ImmunityBio Inc [NASDAQ: IBRX] shares were valued at $3.01 at the most recent close of the market. An investor can expect a potential return of 99.34% based on the average IBRX price forecast.
Analyzing the IBRX fundamentals
Trailing Twelve Months sales for ImmunityBio Inc [NASDAQ:IBRX] were 14.74M which represents 5333.09% growth. Gross Profit Margin for this corporation currently stands at 0.69% with Operating Profit Margin at -23.34%, Pretax Profit Margin comes in at -28.05%, and Net Profit Margin reading is -28.05%. To continue investigating profitability, this company’s Return on Assets is posted at -1.08, Equity is 0.63 and Total Capital is -1.05. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of-1.03.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 2.90 points at the first support level, and at 2.80 for the second support level. However, for the 1st resistance point, the stock is sitting at 3.13, and for the 2nd resistance point, it is at 3.26.
Ratios To Look Out For
To put it in perspective, the Current Ratio for ImmunityBio Inc [NASDAQ:IBRX] is 3.36. On the other hand, the Quick Ratio is 3.21, and the Cash Ratio is 2.61. Considering the valuation of this stock, the price to sales ratio is 174.28.
